|
Market Closed -
OTC Markets
21:59:09 25/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 41.98 USD | +0.02% |
|
-6.19% | +15.46% |
| 09-25 | US FDA approves Mirum's drug for rare bone disorder | RE |
| 09-22 | European Pharma Leaders Push for National Reforms to Boost Investment | DJ |
| Market Cap | 11.75B 13.39B 11.1B 10.11B 18.93B 1,283B 19.07B 133B 51.43B 656B 50.27B 49.18B 2,107B | P/E 2026 * |
11.9x | P/E 2027 * | 12.2x |
|---|---|---|---|---|---|
| Enterprise Value | 10.41B 11.86B 9.83B 8.96B 16.77B 1,137B 16.89B 118B 45.57B 581B 44.54B 43.58B 1,867B | EV / Sales 2026 * |
2.28x | EV / Sales 2027 * | 2.03x |
| Free-Float |
40.65% | Yield 2026 * |
1.07% | Yield 2027 * | 1.07% |
| Markets | Quality | ||
|---|---|---|---|
OTC Markets
| IPSEY | Delayed | |
Deutsche Boerse AG
| I7G0 | Delayed | |
|
Börse Stuttgart
| I7G0 | Delayed |
Last Transcript: Ipsen S.A.
| 1 day | +0.02% | ||
| 1 week | -6.19% | ||
| Current month | -14.59% | ||
| 1 month | -11.81% | ||
| 3 months | -9.72% | ||
| 6 months | -2.58% | ||
| Current year | +15.46% |
| 1 week | 40.66 |  | 42.41 |
| 1 month | 40.66 | | 49.15 |
| Current year | 34.34 | | 51.1 |
| 1 year | 32.68 | | 51.1 |
| 3 years | 25.11 | | 51.1 |
| 5 years | 21.17 | | 51.1 |
| 10 years | 9.1 | | 51.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 59 | 01/07/2020 |
| Chief Executive Officer | 57 | 01/01/2020 | |
Pierrick Lefranc
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Antoine Flochel
BRD | Director/Board Member | 61 | 30/08/2005 |
| Chairman | 68 | 22/11/2010 | |
Carol Xueref
BRD | Director/Board Member | 69 | 01/06/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.02% | -6.19% | - | - | 13.39B | |
| +0.13% | +2.65% | +65.61% | +114.28% | 1,055B | |
| +0.20% | +0.46% | +52.60% | +69.24% | 654B | |
| -0.29% | +0.14% | +20.96% | +70.93% | 467B | |
| -0.85% | +0.98% | +41.29% | +44.38% | 348B | |
| +0.71% | +4.08% | +22.24% | +29.51% | 275B | |
| +1.23% | +0.42% | +14.57% | +12.13% | 258B | |
| +2.11% | +7.51% | +52.89% | +55.37% | 224B | |
| +0.83% | +0.55% | +35.99% | +101.70% | 187B | |
| 0.00% | -10.14% | -29.94% | -60.30% | 171B | |
| Average | +0.33% | +0.60% | +30.69% | +48.58% | 404.26B | |
| Weighted average by Cap. | +0.02% | +1.20% | +41.54% | +67.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.56B 5.2B 4.31B 3.93B 7.35B 498B 7.41B 51.58B 19.98B 255B 19.53B 19.1B 818B | 4.65B 5.3B 4.39B 4.01B 7.5B 508B 7.55B 52.59B 20.37B 260B 19.91B 19.48B 835B |
| Net income | 1.01B 1.15B 954M 870M 1.63B 110B 1.64B 11.42B 4.42B 56.39B 4.32B 4.23B 181B | 982M 1.12B 927M 845M 1.58B 107B 1.59B 11.1B 4.3B 54.78B 4.2B 4.11B 176B |
| Net Debt | -1.34B -1.53B -1.26B -1.15B -2.16B -146B -2.17B -15.13B -5.86B -74.69B -5.73B -5.6B -240B | -2.3B -2.62B -2.17B -1.98B -3.7B -251B -3.73B -25.95B -10.05B -128B -9.82B -9.61B -412B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/09/26 | $41.98 | +0.02% | 1,642 |
| 23/09/26 | $41.97 | -1.03% | 106 |
| 21/09/26 | $42.41 | -5.23% | 241 |
| 17/09/26 | $44.75 | -3.20% | 266 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IPN Stock
- IPSEY Stock
Select your edition
All financial news and data tailored to specific country editions
